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Abstract
Aims: Evidence is sparse on the long‐term outcomes of continent cutaneous
ileocecocystoplasty (CCIC). We hypothesized that obesity, laparoscopic/robotic
approach, and concomitant surgeries would affect morbidity after CCIC and
aimed to evaluate the outcomes of CCIC in adults in a multicenter con-
temporary study.
Methods: We retrospectively reviewed the charts of adult patients from sites
in the Neurogenic Bladder Research Group undergoing CCIC (2007‐2017) who
had at least 6 months of follow‐up. We evaluated patient demographics, sur-
gical details, 90‐day complications, and follow‐up surgeries. the Mann‐
Whitney U test was used to compare continuous variables and χ² and Fisher's
Exact tests were used to compare categorical variables.
Results:We included 114 patients with a median age of 41 years. The median
postoperative length of stay was 8 days. At 3 months postoperatively, major
complications occurred in 18 (15.8%), and 24 patients (21.1%) were readmitted.
During a median follow‐up of 40 months, 48 patients (42.1%) underwent 80
additional related surgeries. Twenty‐three patients (20.2%) underwent at least
one channel revision, most often due to obstruction (15, 13.2%) or incontinence
(4, 3.5%). Of the channel revisions, 10 (8.8%) were major and 14 (12.3%) were
minor. Eleven patients (9.6%) abandoned the catheterizable channel during the
follow‐up period. Obesity and laparoscopic/robotic surgical approach did not
affect outcomes, though concomitant surgery was associated with a higher rate
of follow‐up surgeries.
Conclusions: In this contemporary multicenter series evaluating CCIC, we
found that the short‐term major complication rate was low, but many patients
require follow‐up surgeries, mostly related to the catheterizable channel.
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1 | INTRODUCTION
Patients with bladder dysfunction due to underlying neuro-
logic conditions such as spinal cord injury (SCI), multiple
sclerosis (MS), or spina bifida often have high‐pressure sto-
rage of urine and/or inability to efficiently empty the bladder.
As a result, those with neurogenic bladder (NGB) are often
dependent on anticholinergic medications or bladder botu-
linum toxin injection to improve bladder storage, and clean
intermittent catheterization (CIC) or an indwelling catheter
to empty the bladder.1‐3
When patients with NGB have persistent symptoms of
incontinence or show signs of upper tract deterioration re-
fractory to conservative therapies, surgical management with
augmentation cystoplasty is a potential treatment.4 Aug-
mentation cystoplasty is a reconstructive surgery in which
the bladder is opened and a patch of the bowel is sutured to
the bladder to increase the bladder volume and decrease
bladder pressure and spasticity.5 Different segments of the
gastrointestinal tract have been used for augmentation, such
as the stomach, small bowel, cecum, and colon.4,6‐8 In ad-
dition to augmentation cystoplasty, some patients also un-
dergo concomitant catheterizable channel creation to
facilitate ease of CIC. In cases on concomitant catheterizable
stoma creation, the continent cutaneous ileocecocystoplasty
(CCIC) is a technique that uses a continuous segment of the
bowel: the bladder is augmented with the detubularized ce-
cum and right colon while the terminal ileum is tapered and
used for the catheterizable channel with the ileocecal valve
functioning as a natural continence mechanism.6 One par-
ticular advantage to CCIC is in obese individuals, where the
parallel mesentery to the terminal ileum arising from the
right colic artery allows for the creation of a relatively long
and straight channel that can reach the umbilicus in most
individuals regardless of body mass index (BMI).
There are very few studies looking at outcomes and
complications of augmentation cystoplasty with a catheter-
izable channel in the adult population with most being
single‐site, small cohort studies spanning long time periods
where management of NGB has changed substantially. We
chose to evaluate the complications of CCIC bladder aug-
mentation in the adult population in a multicenter study
with a secondary objective to compare outcomes between
different subgroups of CCIC patients (obese vs nonobese;
those undergoing concomitant surgeries compared to those
undergoing CCIC alone; and laparoscopic/robotic‐assisted vs
open approach). While these subgroups have been the focus
of studies of other urologic patient populations (ie, bladder
cancer), most studies evaluating augmentation cystoplasty
patients with NGB have not specifically examined the effect
of these variables on outcomes. We hypothesized that pa-
tients who were obese or underwent concomitant surgeries
had more complications and required more follow‐up
surgeries.
2 | METHODS
2.1 | Surgical technique
The CCIC technique was first described by Sarosdy in 1992
as a way to augment the native bladder while creating a
catheterizable channel using only one bowel segment.6
Approximately 10 to 15 cm of the cecum and ascending
colon and 10 cm of terminal ileum are harvested en bloc.
The ileal segment is tapered via staple reduction over a 12Fr
to 14Fr catheter to create the catheterizable channel and the
ileocecal valve is reinforced with imbricating sutures to
create the continence mechanism. This portion of the sur-
gery is identical to creation of an Indiana or right colon
pouch.9 The cecum and ascending colon are then detubu-
larized and anastomosed to the bivalved bladder with the
channel brought through the abdominal wall, often at the
umbilicus. The surgery can be performed through an open
or laparoscopic/robotic approach. Open surgery is through a
full laparotomy midline incision. Laparoscopic/robotic cases
are typically performed using hand‐assist or robotic assis-
tance for mobilization of the right colon, with the remainder
of the surgery performed open through a lower midline or
Pfannenstiel incision.
2.2 | Data collection
After institutional review board approval, we retro-
spectively reviewed the charts of 131 patients from seven
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sites in the Neurogenic Bladder Research Group (NBRG)
who underwent CCIC between January 2007 and October
2017. Data were collected in a centralized database using
the Research Electronic Data Capture (REDCap) plat-
form. We included all patients aged 18 years or older at
the time of surgery who had at least 6 months of post-
operative follow‐up and who had not previously under-
gone augmentation cystoplasty or catheterizable channel
creation. We excluded any centers that had fewer than
four patients that met the inclusion criteria. Twenty‐two
patients (five from the Houston Methodist Hospital and
17 from the University of Utah) in this study have had
previous outcomes reported for CCIC, while 92 patients
were new.10,11
2.3 | Patient characteristics
Patient demographic information was collected and in-
cluded: age at surgery, gender, BMI, age‐adjusted Charl-
son Comorbidity Index, etiology of disease, bladder
management before CCIC, and history of bladder botu-
linum toxin injection.
2.4 | Perioperative variables
Details of the surgery were collected and included: op-
erative time, modality (open vs laparoscopic/robotic with
mostly a limited supplemental pelvic Pfannenstiel inci-
sion), concomitant surgeries, and operative times.
2.5 | Outcomes
The primary outcome was 90‐day major complications
(defined as Clavien‐Dindo12 complications grade III‐V),
including death and readmissions. The secondary out-
come was surgery in the total follow‐up period. We de-
fined follow‐up surgeries related to CCIC as all urologic
surgeries, incisional or parastomal hernia repair, and
surgeries related to bowel obstruction, such as lysis of
adhesions. We also included colostomy, since colostomy
could be related to changes in bowel function. We then
compared outcomes between different subgroups of
CCIC patients to examine if obesity (defined as
BMI ≥30 kg/m2), concomitant surgical procedures at the
time of CCIC, or surgical approach (laparoscopic/robotic
assistance) led to an increase in major complications,
readmissions, or follow‐up surgeries. Lastly, a sub‐
analysis was performed comparing patients who had
90‐day major complications vs those who did not to see if
there were any variables associated with complications.
Procedures per person‐year of follow‐up was calculated
by taking the total number of follow‐up surgeries—
including surgeries that were performed more than once
in a particular patient—and dividing it by the cumulative
follow‐up time in years for all of the patients.
2.6 | Statistical analysis
All statistical analyses were conducted using STATA 15
(Stata Corp, College Station, TX) with a two‐sided sig-
nificance level set at P< .05. Medians and interquartile
ranges (IQRs) were reported for continuous variables, as
appropriate. the Mann‐Whitney U test was used to
compare continuous variables. The χ² and Fisher's Exact
tests were used to compare proportions of categorical
variables.
3 | RESULTS
3.1 | Patient characteristics
A total of 114 patients from six sites were included; one
center was excluded since it only had one patient that met
the inclusion criteria. An additional 16 patients were ex-
cluded for the following reasons: follow‐up less than
6 months (n= 12), previous augmentation cystoplasty
(n= 2), and previous catheterizable channel (n = 2). Pa-
tients in this cohort underwent CCIC augmentation cysto-
plasty due to poor bladder compliance or refractory detrusor
overactivity. Most patients in the study had a diagnosis of
the neurogenic bladder (98, 86%) with SCI, MS, and spina
bifida being the most common etiologies (Table 1).
3.2 | Perioperative variables
The median operative time was 313minutes (IQR
258‐382). The hospital length of stay ranged from 3 to
105 days and the median length of stay was eight days
(IQR 7‐12). Almost half of the cohort (45%) had a con-
comitant surgery at the time of CCIC creation (Table 1).
3.3 | Outcomes
In our cohort, 18 patients (15.8%) had a 90‐day major
complication (Clavien‐Dindo grade III‐V) with 10 pa-
tients readmitted due to the major complication and the
other eight patients experiencing the major complication
during the initial postoperative admission. A total of
24 patients (21.1%) were readmitted within 90‐days of
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surgery; for 14 patients, readmission was due to minor
complications. There were no patients who died within
90‐days of surgery. Of the 18 patients who had major
complications within 90 days of surgery, intraabdominal
abscess (4, 3.5%) and bowel leak (4, 3.5%) were the most
common reasons. Other 90‐day complications can be
found in Table 2.
During a median follow‐up period of 39.6 months
(IQR 22.6‐60.8), 48 patients (42.1%) underwent 80
surgeries. The number of procedures per person‐year of
follow‐up was 0.20 (80 procedures/399.01 person‐
years). Twenty‐three patients (20.2%) underwent at
least one catheterizable channel revision, including
minor channel revision (replacement or revision above
the abdominal fascia, injection of a bulking agent, or
stomal dilation) and major channel revision (replace-
ment or revision below abdominal fascia). One of those
patients underwent injection of a bulking agent and a
channel revision below the fascia. Fifteen patients
(13.2%) required revisions due to obstruction of the
channel while four patients (3.5%) had revisions due to
channel incontinence. Eleven patients (9.6%) had
abandonment of the channel (ie, did not perform CIC
through the channel). Four of these patients had pre-
viously undergone channel revisions (one minor revi-
sion and three major revisions). Some reasons for the
abandonment of the channel included the inability to
catheterize, noncompliance, and channel complica-
tions. The most common non‐channel related surgery
was the treatment of bladder stones (11 patients, 9.6%).
Table 3 lists all of the follow‐up surgeries and channel
revision outcomes.
3.4 | Subgroup analysis
3.4.1 | Body mass index
We compared 69 nonobese patients (60.5%) with 45 obese
patients (39.5%). Surgical outcomes in the two groups
were not significantly different (Table 5).
3.4.2 | Concomitant surgeries
A total of 51 patients (44.7%) underwent a total of 74
concomitant surgeries at the time of CCIC, while 63 pa-
tients (55.3%) underwent CCIC alone.Table 4 lists all of
the concomitant surgeries. The most common con-
comitant surgeries were pubovaginal sling (23 patients,
20.2%) and omental flap (23 patients, 20.2%). Patients
who had concomitant surgeries more commonly under-
went an open surgery (44, 86.2% vs 43, 68.2%, P= .03)
with significantly longer operative times (368minutes vs
273minutes, P< .001). The concomitant surgery group
had significantly more follow‐up surgeries (27, 52.9% vs
21, 33.3%, P= .04) (Table 5).
TABLE 1 Patient characteristics, type of surgery, and
postoperative outcomes
Age, y, median (IQR) 41.1 30.0‐53.7
Male, n (%) 36 31.6
Body mass index, kg/m2, median (IQR) 27.5 23.1‐32.8
Age‐adjusted Charlson Comorbidity Index,
0‐1 43 37.7
2‐3 59 51.8
4+ 12 10.5
Etiology of disease, n (%)
Spinal cord injury 52 45.6
Spina bifida 8 7.0
Multiple sclerosis 14 12.3
Other neurologic 24 21.1
Non‐neurologic 16 14.0
History of bladder botulinum toxin injection,
n (%)
31 27.2
Bladder management before augmentation,
n (%)a
Indwelling urethral catheter 27 23.7
Indwelling suprapubic tube 28 24.6
Clean intermittent catheterization 39 34.2
Voiding/leaking/condom catheter 25 21.9
Modality, n (%)
Open 87 76.3
Laparoscopic/robotic 27 23.7
Patients who had a concomitant surgery, n (%) 51 44.7
Operative time, min, median (IQR) 313 258‐382
Hospital length of stay, d, median (IQR) 8 7‐12
90‐d major complication (Clavien‐Dindo
grade III‐V), n (%)
18 15.8
90‐d readmission, n (%) 24 21.1
90‐d mortality, n (%) 0 0
Bladder management after augmentation, n (%)
Indwelling catheter (urethra or channel) 7 6.1
Indwelling suprapubic tube 2 1.8
Clean intermittent catheterization 103 90.3
Other b 2 1.8
Postoperative follow‐up, m, median (IQR) 39.6 22.6‐60.8
Patients with follow‐up surgeries, n (%) 48 42.1
aFive patients had more than one.
bPerineal urethrostomy; cystectomy and urinary diversion.
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3.4.3 | Surgical modality
In the cohort, open surgery was the most common
approach to CCIC creation (n = 87, 76.3%) while 27
patients (23.7%) had a laparoscopic or Da Vinci robot‐
assisted surgery. When comparing those undergoing
open surgery compared to a laparoscopic/robotic ap-
proach, the open group had significantly more con-
comitant surgeries than the laparoscopic/robotic
group (44, 50.6% vs 7, 25.9%, P = .03). No other dif-
ferences in terms of 90‐day readmission, 90‐day
complications, or long‐term surgical revisions were
seen between groups, though the laparoscopic/robotic
group did have significantly shorter follow‐up time
compared to the open group (24.4 months vs 50.8
months, P < .001) (Table 5).
3.4.4 | Major complications
A final subgroup analysis was performed comparing
the 18 patients (15.8%) who had 90‐day major com-
plications (Clavian‐Dindo grade III‐V) with those who
did not have complications (96, 84.2%). There were no
baseline patient characteristics or perioperative vari-
ables associated with major complications. Patients
who had major complications had a longer hospital
length of stay (11 days vs 8 days), but this difference
was not statistically significant (P = .07). Expectedly,
patients who had major complications were also more
likely to have a 90‐day readmission (10, 55.6% vs 14,
14.6%, P < .001).
4 | DISCUSSION
We found that given the procedural complexity of CCIC,
postoperative morbidity, readmission, and mortality were
low. Long‐term, however, a significant number of pa-
tients needed future operations with the majority of these
operations (23 patients, 20.2%) involving revision of the
catheterizable channel.
Patients in the study, had a 90‐day major complica-
tion rate of 15.8%. We did not evaluate minor complica-
tions since they were not reliably or consistently
documented across the different institutions given the
retrospective nature of the study. In a review of 20 studies
on the outcomes of augmentation cystoplasty in adults,
eight studies reported postoperative major complication
rates ranging from 1.7% to 12.5%, though the post-
operative period was not specified and the review only
looked at studies of augmentation cystoplasty without
catheterizable channels.13 In a previous study of 31 pa-
tients who underwent CCIC, we reported an overall 30‐
day complication rate of 51.6% and a 30‐day major
complication rate of 16.1%, which is comparable to our
90‐day complication rate in this expanded cohort.11
Khavari et al10 evaluated 34 CCIC patients and had a
short‐term complication rate of 17.6%, which were all
minor complications that occurred during the immediate
postoperative hospital stay.
In addition to complications and readmissions
within 90 days of surgery, another risk following CCIC
is the need for longer term follow‐up surgeries and re-
visions. In our cohort, 42.1% of patients required further
surgery during a median follow‐up of 39.6 months.
TABLE 2 The 90‐d major
complications by grade
Grade Total (%) Complication
IIIa 7 (6.1) Intraabdominal abscess requiring drain (3)
Bowel leak requiring drain (1)
Urine leak requiring drain (1)
Prolonged ileus requiring esophagogastroduodenoscopy (1)
Pleural effusion requiring chest tube (1)
IIIb 9 (7.9) Bowel leak requiring exploratory laparotomy (3)
Urine leak/fistula requiring exploratory laparotomy (2)
Intraabdominal abscess requiring exploratory laparotomy (1)
Small bowel obstruction requiring gastrostomy tube (1)
Small bowel obstruction requiring exploratory laparotomy (1)
Pyelonephritis with stent migration requiring stent change (1)
IV 2 (1.8) Respiratory distress requiring ICU admission (1)
Altered mental status requiring ICU admission (1)
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The number of procedures per person‐year of follow‐up
was 0.20, which is higher than other studies where rates
of 0.04 procedures per person‐year in pediatric patients
and 0.01 surgeries per person‐year in adults was no-
ted.14,15 Similar to our findings, where cystolitholapaxy
was a very common surgery after CCIC, bladder stone
removal was the most common surgery in both of these
studies.14,15
Although stone procedures were common in our cohort,
the majority of the surgeries were revisions of the catheter-
izable channel (23 patients, 20.2%). A study of pediatric pa-
tients who had undergone augmentation cystoplasty with a
catheterizable channel showed that complications related to
the channel were dependent on the type of channel.16 Rates
of channel abandonment and revisions were highest in pa-
tients with a reconfigured ileum (Monti), lower in patients
with an appendicovesicostomy (Mitrofanoff), and lowest in
patients with a tapered ileum and reinforced ileocecal valve
(CCIC).16 In a similar study, O'Connor et al17 evaluated the
outcomes of different types of catheterizable channels and
found that 39% of patients underwent a major channel re-
vision during a median follow‐up period of 60 months. The
channel incontinence and revision rates were higher in the
ileal group than in the appendiceal group, though most of
the ileal group had Monti channels and none of them un-
derwent a CCIC.17 Two different long‐term series evaluating
patients that underwent ileocystoplasty with either a Mi-
trofanoff or Monti catheterizable channel had sustainable
continent catheterizable channels with a low rate of revision
surgery (1 out of 13 patients, 7.7%, median follow‐up
44 months18; 4 out of 29 patients, 13.8%, median follow‐up
66 months19). Of note, neither of these studies specifically
listed the type of channel for patients requiring revisions. In
our earlier report, we showed that CCIC has superior out-
comes compared with other types of channels.11 In fact, 50%
of patients who underwent a tunneled channel creation (ie,
Mitrofanoff, Monti) required a subsequent procedure related
to leakage or stenosis compared to 13% of patients who un-
derwent a CCIC during a median follow‐up of 16 months.11
The rate of channel revision in our current study was ap-
proximately 20%, but our median follow‐up period was more
than double at 40 months. Of note, the vast majority of re-
visions were due to obstruction rather than leakage, which is
likely attributed to the efficacy of the reinforced ileocecal
valve as a continence mechanism.
TABLE 3 Follow‐up surgeries and channel revisions
Patients with follow‐up surgeries, n (%) 48 (42.1)
Total number of surgeriesa 80
Bladder stone, n (%) 11 (9.6)
Ureteral or kidney stone, n (%) 3 (2.6)
Bladder neck closure, n (%) 4 (3.5)
Artificial urinary sphincter, n (%) 2 (1.8)
Suprapubic tube, n (%) 3 (2.6)
Perineal urethrostomy, n (%) 1 (0.9)
Cystectomy, urinary diversion, n (%) 1 (0.9)
Ventral hernia repair, n (%) 6 (5.3)
Parastomal hernia, n (%) 7 (6.1)
Colostomy, n (%) 3 (2.6)
Other abdominal surgery, n (%)b 5 (4.4)
Catheterizable channel revision, n (%) 23 (20.2)
Injection of bulking agent 2 (1.8)
Dilation of channel 3 (2.6)
Superficial revision (above fascia) 9 (7.9)
Deep revision (below fascia) 9 (7.9)
Full replacement 1 (0.9)
Reason for channel intervention, n (%)
Obstruction 15 (13.2)
Leakage 4 (3.5)
Otherc 4 (3.5)
Abandonment of channel, n (%) 11 (9.6)
Notes: One patient underwent two different types of channel revision; Eight
patients underwent multiple surgeries of the same type.
aSixteen patients underwent more than one type of surgery.
bExploratory laparotomy; excision of fistula tract; three unknown.
cComplex wound infection; bowel leak; facilitate ventral hernia.
TABLE 4 Concomitant surgeries
Patients who had a concomitant surgery, n (%) 51 (44.7)
Total number of surgeries 74
Pubovaginal sling, n (%) 23 (20.2)
Mesh urethral sling, n (%) 3 (2.6)
Bladder neck closure, n (%) 6 (5.3)
Bladder neck reconstruction, n (%) 2 (1.8)
Omental flap, n (%) 23 (20.2)
Muscle flap, n (%) 2 (1.8)
Umbilical hernia repair, n (%) 5 (4.4)
Ventral hernia repair, n (%) 2 (1.8)
Parastomal hernia repair, n (%)a 1 (0.9)
Ureteral reimplant, n (%) 1 (0.9)
Colostomy, n (%) 2 (1.8)
Antegrade continence enema, n (%) 1 (0.9)
Other, n (%) b 3 (2.6)
Note: Prosthesis reservoir removal.
aPatient with prior colostomycolostomy.
bDrainage of pelvic abscess; resection of pelvic mass; penile.
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In our first subgroup analysis, we evaluated the effect
of BMI in adult patients on augmentation cystoplasty.
Obese patients may need CCIC or other types of aug-
mentation cystoplasty with a catheterizable channel be-
cause of challenges with catheterizing due to their body
habitus.20 However, creation of a catheterizable channel
is technically much more difficult in obese patients and
may be prone to a higher channel‐related complication
rate. In a study of 385 patients with a history of aug-
mentation cystoplasty during childhood, Husmann found
that obese patients performing CIC through the urethra
were more likely to have problems with CIC compared
with obese patients performing CIC through an abdom-
inal stoma.20 However, studies of obese patients with
stomas due to bladder cancer, neurogenic bladder, or
myelodysplasia demonstrate that they are more likely to
develop complications, such as parastomal hernia, stomal
retraction, and stomal stenosis.21‐23 Our results did not
show any effect of obesity on the outcomes of CCIC; this
may be due to one of the technical advantages of CCIC, in
which the bowel segment has a relatively parallel me-
senteric blood supply to the terminal ileum, allowing for
the creation of a lengthy straight catheterizable channel
even in obese patients.
In our second subgroup analysis, we found that pa-
tients who had concomitant surgeries at the time of CCIC
were significantly more likely to require follow‐up sur-
geries. Two‐thirds of the patients who had concomitant
surgeries underwent a bladder outlet procedure, such as a
pubovaginal sling, mesh urethral sling, or bladder neck
closure. In line with our results, Welk et al15 found that a
simultaneous continence procedure at the time of aug-
mentation cystoplasty was a significant predictor of fu-
ture surgical procedures. The need for a concomitant
bladder outlet procedure at the time of augmentation
cystoplasty has not been well established. Among the
different sites involved in this study, the manner in
which the urologists decided when to perform con-
comitant continence procedures varied. Some urologists
preferred to perform a bladder outlet surgery at a later
stage only if necessary,24 while others based their deci-
sion for a concomitant procedure on the severity of the
patient's incontinence, presence or lack of trabeculation
or hydronephrosis, and urodynamic findings.10
Our third subgroup analysis evaluated the effect of
surgical modality on the outcomes of CCIC. Augmenta-
tion cystoplasty is often performed through an open
midline incision. With the advent of new technology and
in an attempt to reduce morbidity, minimally invasive
approaches have become more common. Gill et al25 first
described a partial laparoscopic approach for augmenta-
tion cystoplasty in 2000 and Elliott et al26 described a
complete laparoscopic approach in 2002. Cohen et al27T
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compared the outcomes of open augmentation cysto-
plasty with robotic augmentation cystoplasty in a pedia-
tric cohort and found that complications, hospital length
of stay, blood loss, and narcotic use between the two
groups were comparable, though the operative time in
the robotic cohort was significantly longer. Similarly, we
did not find any differences in outcomes between the
open and the laparoscopic/robotic assisted approaches.
The median operative times between the two groups were
not significantly different. Thus, our study shows that
CCIC through a minimally invasive approach is feasible
and can be equally efficient in experienced hands.
There are several limitations to this study. We focused
on surgical morbidity rather than functional outcomes, such
as bladder capacity and degree of continence, since pre-
operative and postoperative urodynamics data were not
available for all patients. Many studies in the literature al-
ready show that the majority of patients who undergo
augmentation cystoplasty for NGB experience an improve-
ment in bladder capacity, compliance, and continence, but
what is lacking are large cohort studies that evaluate short‐
and long‐term complications of one particular type of aug-
mentation cystoplasty, such as CCIC.13,19,28,29 Since we
conducted a retrospective chart review study, we were un-
able to accurately assess certain long‐term complications of
augmentation cystoplasty, such as metabolic disturbances,
renal failure, and symptomatic urinary tract infection. We
were also unable to assess patient‐reported quality‐of‐life
measures and outcomes, such as bowel dysfunction, degree
of urinary incontinence, ease of bladder management/CIC,
and overall satisfaction with urinary outcomes. Although a
multicenter study has the advantage of providing a larger
cohort, in this particular case, it adds to the heterogeneity of
surgical techniques and preoperative and postoperative
management. Due to the number of sites involved in the
study and differing numbers of patients per site, a subset
analysis comparing outcomes between sites was not fea-
sible. There is certainly a risk of sampling bias in this study,
though all of the participating sites utilized consecutive
patient selection to minimize this bias. We also had a small
sample size for subgroup analyses, which could explain why
there were few significant differences between subgroups.
Despite these limitations, this is the largest adult series in
the literature evaluating the long‐term morbidity outcomes
of CCIC. Since the median follow‐up period for this study
was a little more than 3 years, it is important to continue
tracking the complications and follow‐up surgeries of these
patients to evaluate longer‐term outcomes, as we may find
that a majority of patients will need a follow‐up surgery by
10 or 20 years following the original augmentation cysto-
plasty. A randomized controlled‐trial of different augmen-
tation cystoplasty techniques would not be logistically
feasible, but a prospective study with well‐defined outcomes
that incorporated patient‐reported outcomes would be
beneficial to the field.
5 | CONCLUSIONS
In this multi‐center, contemporary study of CCIC, we
found that the short‐term major complication rate was
low, but many patients required follow‐up surgeries,
mostly related to the catheterizable channel.
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